medical devices

Instruments, implants and equipment used to diagnose and treat patients, including orthopaedic implants such as hip and knee replacements.

Industry · 13 companies · 6 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“AbbVie’s medical device products are subject to extensive regulation by the FDA in the United States.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ABT Abbott Laboratories

    Sells it 45%, $5.8B a quarter“Medical Devices grew 6.9% in Q3 (7.4% excluding FX) and 9.6% in 9M to $17.218B from $15.712B (7.8% excluding FX).”

    Latest 8-KExecutive pay ·

    Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

  • AMRO Amaero Inc.

    Supplies it“We produce spherical powders for AM processes, specifically engineered for the highest-demand, highest-value applications in defense, aerospace, space, medical devices, and industrial manufacturing.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernAccounting issueCustomer concentration ·

    Titanium and refractory metal powder maker scales up for defense and aerospace; IPO funding extends runway only into Q2 2027

  • DHR Danaher Corporation

    Sells it“Masimo, a patient-monitoring technology business with approximately $1.5B of 2025 revenue, joined Diagnostics.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • EMI Encore Medical, Inc.

    Sells it“We develop, manufacture, and market septal occlusion devices for the repair of certain cardiac defects.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

  • ISRG Intuitive Surgical

    Sells it 84%, $8.5B a year“We offer a comprehensive suite of stapling, energy, and core instrumentation for our da Vinci surgical systems.”

    Latest 8-KLeadership change ·

    Humana insurance chief Aaron Martin appointed independent director, expanding the board effective Jan. 1, 2027.

  • JNJ Johnson & Johnson

    Sells it 36%, $33.8B a year“The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a wide range of acute and elective procedures.”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • MDT Medtronic

    Sells it 100%, $9.7B a quarter“Product adoption and successful commercialization—including pulsed-field ablation, Hugo robotic-assisted surgery, TAVR, renal denervation, ECMO and integrated spine offerings—remain important growth drivers, alongside regulatory approvals and safe, effective use.”

    Latest 8-KPositiveDeal completedLeadership changeExecutive pay ·

    MiniMed separation completed after the exchange offer was 5.4x subscribed.

  • NOVT NOVANTA INC

    Sells it 52%, $159.7M a quarter“Both segments primarily serve OEM customers; Automation Enabling Technologies serves industrial, robotics, life-sciences and medical-laser applications, while Medical Solutions supplies surgical, imaging/RFID and operating-room technologies.”

    Latest 10-QQ3 FY2026Restructuring ·

    Riverpoint expands surgical consumables, but acquisition charges, amortization and financing costs overwhelm gains from stronger automation.

    • Revenue$305.0MYoY +23.1%
    • Net income$2.0MYoY −81.1%
  • RGNA Regenlab USA Inc.

    Sells it“RegenKit is our proprietary, single-use, sterile, closed-system medical device kit designed for point-of-care preparation of autologous PRP.”

    Latest S-1/Aamended IPO prospectusMixedBankruptcy / going concernRestatementAccounting issue ·

    Sells platelet-rich plasma kits; founder Antonino Turzi retains 87.66% ownership after the offering.

  • SYK Stryker Corporation

    Sells it 73%, $4.8B a quarter“Stryker also cited uncertainty about the operational and financial effects of the cybersecurity incident first reported March 11, 2026, as well as costs associated with EU medical-device compliance, recalls, and regulatory and legal matters.”

    Latest 8-KLeadership change ·

    Board expands to add Quest Diagnostics CEO James E. Davis, effective Jan. 1, 2027.

  • SYTN Syntiant Corp.

    Supplies it“We currently ship neural processors and AI software for use in regulated healthcare devices, where continuous, ultra‑low‑power on‑device inference is required to meet strict power, latency, reliability, and privacy requirements.”

    Latest S-1/Aamended IPO prospectusNegativeCustomer concentration ·

    Sells microphones and on-device AI chips; acquired Knowles operations supplied 97% of FY2025 revenue.

  • TEL TE Connectivity

    Supplies it, part of Industrial Solutions“We specialize in the design and manufacture of advanced surgical, imaging, and interventional device solutions.”

    Latest 10-KFY2026Positive ·

    AI data-center and grid demand made Industrial Solutions the largest operating-profit contributor, reducing reliance on automotive.

    • Revenue$19.9BYoY +15.2%
    • Net income$3.3BYoY +76.6%

Feedback